Opinions+

Opinions+ Irfan Khan

STAT Plus: Developing new drugs starts with building the next generation of clinical investigators

Opinions+ Christine Swisher and Gabriel Seidman

STAT Plus: 4 concrete steps to realize the AI Bill of Rights for clinical decision support software

Opinions+ Patricia Hurter

STAT Plus: Continuous manufacturing can help pharma companies save time, money, and more

Opinions+ Thomas Newcomer

STAT Plus: Removing barriers to biosimilar adoption in the United States

Opinions+ Ashley Beecy, Steve Miff, and Karandeep Singh

STAT Plus: HHS’s proposed rule prohibiting discrimination via algorithm needs strengthening

Opinions+ Meg Richards

STAT Plus: The need for regulatory grade evidence: Are you in the stadium or the sandbox?

Opinions+ Preston Toole

STAT Plus: How machine learning and automation can solve biomanufacturing scale-up challenges

Opinions+ Justin Norden

STAT Plus: Clinical validation will save digital health’s reputation

Opinions+ Sajith Wickramasekara

STAT Plus: How to close biopharma’s data science and engineering skills gap

Opinions+ Jeff Levin-Scherz and Andrey Ostrovsky

STAT Plus: 10 tips for vendors seeking to create or expand digital health and virtual health solutions

Opinions+ Michael J. Alkire and Soumi Saha

STAT Plus: How the U.S. can mitigate and prevent medical device shortages

Opinions+ Emily Johnson and Jenna Phillips

STAT Plus: QR codes can help pharmaceutical companies in two big ways

Opinions+ Mark P. Sendak, Nicholson Price, and Suresh Balu

STAT Plus: A market failure is preventing efficient diffusion of health care AI software

Opinions+ Scott Swain, Kristin M. Zimmerman Savill, and Bruce Feinberg

STAT Plus: Pharma’s role in value-based care starts with value-based research

Opinions+ Marc Herant and Jason Brauner

STAT Plus: Incentives to spur repurposing of existing generics for novel uses would open a new paradigm in drug R&D

Opinions+ Nicole Paraggio, Nicole van Poppel, and Selen Karaca-Griffin

STAT Plus: Reimagining R&D can cut drug development costs from billions to millions

Opinions+ Neil Dhawan

STAT Plus: The future of pharma and health care will come in small (molecule) packages

Opinions+ Edward M. Kaye

STAT Plus: What biotech can learn from past stock market downturns

Opinions+ Abhinav Shashank and Smriti Khera

STAT Plus: Biopharma companies need digital portfolios to succeed in a disease management future

Opinions+ Birgit Girshick

STAT Plus: Biopharma’s response to the next pandemic depends on collaboration and the ability to learn and fail fast

Opinions+ Rod MacKenzie

STAT Plus: How PDUFA VII can catalyze ‘lightspeed’ vaccine and drug development

Opinions+ Jose-Carlos Gutiérrez-Ramos

STAT Plus: Manufacturing at the edge: smaller, localized, and agile factories will be key to biopharma drug production

Opinions+ James Biggins

STAT Plus: Med tech companies that approach value-based care contracting wisely can earn first-mover advantage

Opinions+ Jim King and Philip Burton

STAT Plus: What’s blocking health care boards’ progress in diversity, equity, and inclusion?

Opinions+ Catherine Gregor

STAT Plus: Patient engagement: The true benchmark in clinical trials

Opinions+ Laurent Levy

STAT Plus: Building a better on-ramp for health innovation

Opinions+ Prasad Dindigal

STAT Plus: Forget the hype and embrace the reality: How AI can improve health outcomes right now

Opinions+ Elizabeth Ruzzo

STAT Plus: 8 reasons ‘move fast and break things’ doesn’t work for health care companies

Opinions+ Andy Plump

STAT Plus: Maintaining trust in science is crucial to public health. Here’s how the biopharma industry can help